The Biden administration this morning, as widely expected, announced it is rescinding the Trump administration’s regulatory requirement that community health centers pass along all their 340B savings on insulin and EpiPen-like devices to low-income patients with high-cost or no health insurance.
The U.S. Health and Human Services Department (HHS) posted the rescission notice for public inspection early today. It is scheduled to be formally published in the Federal Register tomorrow.
The Biden administration this morning, as widely expected, announced it is rescinding the Trump administration’s regulatory requirement that community health centers pass along all their 340B savings on insulin and EpiPen-like devices to low-income patients with high-cost or no health insurance.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
